Welcome to the 2nd Biomarker Insights Summit!

Please note: This meeting is taking place in-person only at the Embassy Suites By Hilton - New Orleans Convention Centre,

and online attendance will not be available.

In the past few years, biomarker screening tools have emerged as a promising and innovative approach to treating some cancers. But despite this excitement, obstacles remain when trying to identify new biomarkers that predict sensitivity to current therapies.

This whole day summit will bring together a wealth of knowledge on multiplex immunofluorescence and AI image analysis tools to maximize the successes of biomarker driven trials.

Via keynote presentations and interactive panel discussions, attend this event to:

biomarkers circle
biomarkers circle
biomarkers circle

Explore the growing need for the identification of new biomarkers predictive for sensitivity to anti-PD1 and/or anti-PDL1 therapies

Tap into digital pathology workflows and the use of multiplex immunofluorescence being an accessible, flexible, and valuable tool for validating protein and RNA biomarkers in situ when evaluating clinical utility of compounds of interest

Assess considerations for reproducible image analysis and novel AI algorithms

Hear from Past Attendees:

" This conference is a good opportunity for industry leaders to be able to come together and learn how different companies will tackle challenges from different perspectives, as well as allowing us to learn from each other ”


“The quality of attendees makes a great conference and the people that attended this meeting were absolutely first-rate”


Hosted By:

Ultivue LOGO

Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers to realize the promise of personalized medicine. The company has launched products and services that will seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.